P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0

Documenti analoghi

• S292: SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL
  di: N. Cooper, et al.
  Pubblicazione: (2022-06-01)
• PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
  di: Francesco Zaja, et al.
  Pubblicazione: (2023-08-01)
• P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
  di: Nichola Cooper, et al.
  Pubblicazione: (2023-08-01)
• Use and Effects of Eltrombopag in Pregnant Woman With Difficult-to-Treat Idiopathic Thrombocytopenic Purpura (ITP)
  di: Graciella Calsolari Figueiredo de Farias, et al.
  Pubblicazione: (2025-01-01)
• Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
  di: Hong Chang, et al.
  Pubblicazione: (2023-11-01)